Teicoplanin combined with conventional vancomycin therapy for the treatment of pulmonary methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis infections

BACKGROUND Vancomycin and teicoplanin are both antibiotics that have significant antimicrobial effects on Gram-positive cocci.AIM To explore the value of teicoplanin combined with conventional(vancomycin only)anti-infective therapy for the treatment of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis pulmonary infections.METHODS A total of 86 patients with methicillin-resistant Staphylococcus aureus or methicillin-resistant Staphylococcus epidermidis pulmonary infections,treated in our hospital between January 2018 and February 2020,were assigned to the study and control groups using a random number table method,with 43 patients in each group.The control group received conventional treatment(vancomycin),and the study group received both teicoplanin and conventional treatment.The following indicators were assessed in both groups:the time required for symptom relief,treatment effectiveness,serum levels of inflammatory factors(procalcitonin,interleukin-1β,tumor necrosis factor-α,C-reactive protein),clinical pulmonary infection scores before and after treatment,and the incidence of adverse reactions.RESULTS Patients in the study group were observed to have faster cough and expectoration resolution,white blood cell count normalization,body temperature normalization,and rales disappearance than patients in the control group(all P<0.05);the total rate of effectiveness was 93.02%in the study group,higher than the 76.74%in the control group(P<0.05).The pre-treatment serum levels of procalcitonin,interleukin-1β,tumor necrosis factor-α,and C-reactive protein as well as the clinical pulmonary infection scores were similar among the patients in both groups.However,the post-treatment serum levels of procalcitonin,interleukin-1β,tumor necrosis factor-α,and C-reactive protein as well as the clinical pulmonary infection scores were significantly lower in the study group than in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the groups.CONCLUSION Compared with conventional(vancomycin only)therapy,teicoplanin and vancomycin combination therapy for patients with pulmonary methicillinresistant Staphylococcus aureus and methicillin-resistant Staphylococcus epidermidis infections can improve patient clinical symptoms,modulate serum inflammatory factor levels,and improve treatment efficacy,without increasing the risk of adverse reactions.

五倍子对表皮葡萄球菌的抗菌作用及其形态学变化

目的观察五倍子乙醇提取物对表皮葡萄球菌的体外抗菌活性及其形态学变化。方法采用新的中药抑菌实验方法对五倍子乙醇提取物进行124株表皮葡萄球菌的最低抑菌浓度测定,同时用显微镜观察用药后菌细胞形态和结构改变。结果五倍子乙醇提取物对43株耐甲氧西林的表皮葡萄球菌(MRSE)和81株甲氧西林敏感的表皮葡萄球菌(MSSE)的MIC90分别为0.288、0.144mg/mL;在显微镜下,经五倍子处理的表皮葡萄球菌菌细胞逐渐膨胀、增大,可能是五倍子进入菌细胞后,其抗菌物质与菌细胞发挥杀菌作用所致。膨胀到一定大小时细胞内含物逐渐消失。结论五倍子乙醇提取物对表皮葡萄球菌具有较强的抗菌作用,可使菌细胞形态发生显著改变。

五倍子乙醇提取物对表皮葡萄球菌的体外抗菌活性研究

目的 观察五倍子乙醇提取物对表皮葡萄球菌的体外抗菌活性 ,为临床应用和新药研究提供依据。方法 采用新的中药抑菌实验方法 ,对五倍子提取物进行 2 36株表皮葡萄球菌的最低抑菌浓度测定 ,并与五倍子水煎剂进行抑菌效果对比。结果 五倍子提取物对 2 36株表皮葡萄球菌中的 12 7株耐甲氧西林表皮葡萄球菌 (methicillin -resistantstaphylococcusepider midis ,MRSE)和 10 9株甲氧西林敏感的表皮葡萄球菌 (methicillin -sensitivestaphylococcusepidermidis,MSSE)的MIC90 分别为 1.15和 0 .2 88mg·ml-1。结论 五倍子乙醇提取物对 2 36株表皮葡萄球菌具有较强的抑菌作用。

五倍子乙醇提取物对124株表皮葡萄球菌体外抗菌活性的观察

目的 观察五倍子乙醇提取物对表皮葡萄球菌的体外抗菌活性。方法 采用新的中药抑菌实验方法对五倍子乙醇提取物进行124株表皮葡萄球菌的最低抑菌浓度测定。结果 五倍子乙醇提取物对43株耐甲氧西林表皮葡萄球菌(methicillin-resistant staphylococcus epidermidis,MRSE)和81株甲氧西林敏感的表皮葡萄球菌(methicillin-sensitive staphylococcus epidermidis,MSSE)的MIC50、MIC90分别为0.072、0.072、0.288、0.144 mg/mL。结论 五倍子乙醇提取物对124株表皮葡萄球菌具有较强的抑菌力,说明五倍子是极具开发前景的抗感染中药。